NASDAQ:UBX Unity Biotechnology (UBX) Stock Forecast, Price & News $3.42 -0.12 (-3.39%) (As of 01:19 PM ET) Add Compare Share Share Today's Range$3.27▼$3.6150-Day Range$1.49▼$3.5452-Week Range$1.46▼$18.50Volume95,237 shsAverage Volume360,797 shsMarket Capitalization$49.13 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Unity Biotechnology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside99.7% Upside$6.75 Price TargetShort InterestHealthy7.39% of Float Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$15,097 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.41) to ($3.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector274th out of 986 stocksPharmaceutical Preparations Industry119th out of 481 stocks 3.5 Analyst's Opinion Consensus RatingUnity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.75, Unity Biotechnology has a forecasted upside of 99.7% from its current price of $3.38.Amount of Analyst CoverageUnity Biotechnology has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.39% of the float of Unity Biotechnology has been sold short.Short Interest Ratio / Days to CoverUnity Biotechnology has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Unity Biotechnology has recently decreased by 17.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUnity Biotechnology does not currently pay a dividend.Dividend GrowthUnity Biotechnology does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnity Biotechnology has received a 74.69% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Unity Biotechnology is -0.60. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 3 people have searched for UBX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Unity Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Unity Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,097.00 in company stock.Percentage Held by InsidersOnly 4.90% of the stock of Unity Biotechnology is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Unity Biotechnology are expected to grow in the coming year, from ($3.41) to ($3.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unity Biotechnology is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unity Biotechnology is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUnity Biotechnology has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Unity Biotechnology (NASDAQ:UBX) StockUnity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.Read More Receive UBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address UBX Stock News HeadlinesMay 27, 2023 | americanbankingnews.comUnity Biotechnology (NASDAQ:UBX) Price Target Increased to $6.00 by Analysts at CitigroupMay 15, 2023 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Unity Biotechnology (UBX)June 9, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 12, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Unity Biotechnology, Inc. Issued By HC Wainwright (NASDAQ:UBX)May 10, 2023 | msn.comHC Wainwright & Co. Reiterates Unity Biotechnology (UBX) Buy RecommendationMay 10, 2023 | markets.businessinsider.comUnity Biotechnology (UBX) Gets a Buy from H.C. WainwrightMay 9, 2023 | yahoo.comUNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business UpdatesMay 9, 2023 | finance.yahoo.comUNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business UpdatesJune 9, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.April 29, 2023 | americanbankingnews.comFY2026 Earnings Forecast for Unity Biotechnology, Inc. Issued By Wedbush (NASDAQ:UBX)April 25, 2023 | markets.businessinsider.comWhere Unity Biotechnology Stands With AnalystsApril 25, 2023 | markets.businessinsider.comUnity Biotechnology (UBX) Gets a Buy from WedbushApril 25, 2023 | msn.comWedbush Maintains Unity Biotechnology (UBX) Outperform RecommendationApril 24, 2023 | markets.businessinsider.comUnity Biotechnology (UBX) Receives a Rating Update from a Top AnalystApril 24, 2023 | finance.yahoo.comUnity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's EyleaApril 24, 2023 | finance.yahoo.comUNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular EdemaApril 21, 2023 | msn.comUnusual Call Option Trade in Unity Biotechnology (UBX) Worth $15.00KApril 1, 2023 | americanbankingnews.comFY2026 EPS Estimates for Unity Biotechnology, Inc. (NASDAQ:UBX) Reduced by AnalystMarch 31, 2023 | americanbankingnews.comUnity Biotechnology (NASDAQ:UBX) Earns Buy Rating from HC WainwrightMarch 30, 2023 | americanbankingnews.comHC Wainwright Comments on Unity Biotechnology, Inc.'s Q1 2023 Earnings (NASDAQ:UBX)March 30, 2023 | americanbankingnews.comUnity Biotechnology (NASDAQ:UBX) Price Target Cut to $5.00March 28, 2023 | markets.businessinsider.comExpert Ratings for Unity BiotechnologyMarch 28, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Unity Biotechnology (UBX)March 28, 2023 | americanbankingnews.comMizuho Trims Unity Biotechnology (NASDAQ:UBX) Target Price to $6.00March 28, 2023 | americanbankingnews.comCitigroup Cuts Unity Biotechnology (NASDAQ:UBX) Price Target to $5.00March 27, 2023 | marketwatch.comUnity Biotechnology Shares Plumb New Depths After Study Setback >UBXMarch 27, 2023 | msn.comUnity Biotechnology Nosedives after Underwhelming Drug ResultsSee More Headlines UBX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UBX Company Calendar Last Earnings5/09/2023Today6/09/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:UBX CUSIPN/A CIK1463361 Webwww.unitybiotechnology.com Phone(650) 416-1192FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.75 High Stock Price Forecast$10.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+95.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($5.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,930,000.00 Net MarginsN/A Pretax Margin-21,981.78% Return on Equity-85.06% Return on Assets-43.91% Debt Debt-to-Equity Ratio0.13 Current Ratio3.95 Quick Ratio3.95 Sales & Book Value Annual Sales$236,000.00 Price / Sales210.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book0.73Miscellaneous Outstanding Shares14,365,000Free Float13,661,000Market Cap$49.56 million OptionableNot Optionable Beta0.69 Key ExecutivesDr. Anirvan Ghosh Ph.D. (Age 59)CEO & Director Comp: $1.08MDr. Nathaniel E. David A.B. (Age 55)Ph.D., Co-Founder & Exec. Director Comp: $40kMs. Lynne Marie Sullivan (Age 56)CFO & Head of Corp. Devel. Comp: $730.82kDr. Jan M. van DeursenFounderDr. Judith Campisi Ph.D.FounderMr. Daohong Zhou M.D.FounderMr. Nathan Guz Ph.D.VP of OperationsMr. Alexander Azoy (Age 47)Chief Accounting Officer & Principal Accounting Officer Dr. Przemyslaw Sapieha Ph.D.Chief ScientistMr. Alexander Hieu Nguyen J.D. (Age 46)Gen. Counsel & Corp. Sec. More ExecutivesKey CompetitorsGenprexNASDAQ:GNPXNextCureNASDAQ:NXTCMustang BioNASDAQ:MBIOMEI PharmaNASDAQ:MEIPBeyondSpringNASDAQ:BYSIView All CompetitorsInsiders & InstitutionsArete Wealth Advisors LLCBought 10,392 shares on 5/22/2023Ownership: 0.072%Geode Capital Management LLCBought 31,882 shares on 5/16/2023Ownership: 0.856%Founders Fund V Management LLCSold 442,579 shares on 5/16/2023Ownership: 0.342%State Street CorpBought 13,300 shares on 5/16/2023Ownership: 0.266%Susquehanna International Group LLPSold 5,900 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions UBX Stock - Frequently Asked Questions Should I buy or sell Unity Biotechnology stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UBX shares. View UBX analyst ratings or view top-rated stocks. What is Unity Biotechnology's stock price forecast for 2023? 5 brokers have issued twelve-month price targets for Unity Biotechnology's stock. Their UBX share price forecasts range from $5.00 to $10.00. On average, they predict the company's stock price to reach $6.75 in the next year. This suggests a possible upside of 95.7% from the stock's current price. View analysts price targets for UBX or view top-rated stocks among Wall Street analysts. How have UBX shares performed in 2023? Unity Biotechnology's stock was trading at $2.74 on January 1st, 2023. Since then, UBX shares have increased by 25.9% and is now trading at $3.45. View the best growth stocks for 2023 here. Are investors shorting Unity Biotechnology? Unity Biotechnology saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 952,200 shares, a decrease of 17.2% from the April 30th total of 1,150,000 shares. Based on an average daily volume of 417,800 shares, the days-to-cover ratio is presently 2.3 days. Approximately 7.4% of the company's stock are sold short. View Unity Biotechnology's Short Interest. When is Unity Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our UBX earnings forecast. How were Unity Biotechnology's earnings last quarter? Unity Biotechnology, Inc. (NASDAQ:UBX) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.34. When did Unity Biotechnology's stock split? Unity Biotechnology shares reverse split on the morning of Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Unity Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK). When did Unity Biotechnology IPO? (UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager. What is Unity Biotechnology's stock symbol? Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX." Who are Unity Biotechnology's major shareholders? Unity Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (2.01%), Geode Capital Management LLC (0.86%), BlackRock Inc. (0.75%), ExodusPoint Capital Management LP (0.65%), Renaissance Technologies LLC (0.54%) and Dimensional Fund Advisors LP (0.47%). Insiders that own company stock include Anirvan Ghosh, Jamie Dananberg and Nathaniel E David. View institutional ownership trends. How do I buy shares of Unity Biotechnology? Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Unity Biotechnology's stock price today? One share of UBX stock can currently be purchased for approximately $3.45. How much money does Unity Biotechnology make? Unity Biotechnology (NASDAQ:UBX) has a market capitalization of $49.56 million and generates $236,000.00 in revenue each year. The company earns $-59,930,000.00 in net income (profit) each year or ($5.02) on an earnings per share basis. How can I contact Unity Biotechnology? The official website for the company is www.unitybiotechnology.com. The company can be reached via phone at (650) 416-1192 or via email at ir@unitybiotechnology.com. This page (NASDAQ:UBX) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unity Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.